Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inpatients or outpatients with Major Depressive Disorder characterized by a recurrent Major Depressive Episode with Montgomery and Asberg Depression Rating Scale (MADRS) total score =\> 30
You may not be if
Patient is at immediate risk for suicidal behavior
Patient with psychotic features, catatonic features, seasonal pattern or postpartum onset
Patients with a current depressive episode secondary to a general medical disorder
Patients with a lifetime history or presence of bipolar disorder, psychotic disorder, panic disorder and antisocial personality disorder
Patients with severe or unstable concomitant medical conditions
Pregnant, breastfeeding, or likely to become pregnant during the study
Treated with escitalopram within 6 months before the study, or who have had an adverse reaction to escitalopram
The investigator will evaluate whether there are other reasons why a patient may not participate.
Clareo Health | Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
